Wednesday, July 8, 2026

pharma · Diabetic Macular Edema · Hypercholesterolemia · REGN

Regeneron UK

Regeneron UK is a pharma organization headquartered in Tarrytown, USA. It trades on NYSE under ticker REGN. Primary therapeutic focus areas include Diabetic Macular Edema, Hypercholesterolemia, Asthma, Macular Degenerati

Tarrytown, USA HQ
16,715 Employees
Public company Type
REGN · NYSE Ticker
Company details
Clinical program

Intravitreal Aflibercept Injection

Phase 2 · small molecule · Diabetic Macular Edema

Intravitreal Aflibercept Injection for Diabetic Macular Edema is a Phase 2 program (small_molecule) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).

← All Regeneron UK Limited projects Phase 2 small molecule completed

Internal code VGFT-OD-0706

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Regeneron UK Limited
Phase
Phase 2
Modality
small_molecule
Indication
Diabetic Macular Edema
Status
completed
Trials
1